ANIK
BEARISH
$14.2
Live
Anika Therapeutics, Inc. · NASDAQ
Target $17.5
(+23.2%)
$7.87
52W Range
$16.7
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$204.78M
P/E
N/A
ROE
-6.7%
Profit margin
-9.6%
Debt/Equity
0.18
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.
Key Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Recent 6-month price surge (+63.8%) reflects strong short-term momentum
Analyst consensus is 'strong_buy' with a price target above current levels
Key Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation
No free cash flow or operating cash flow data available, raising sustainability concerns
No dividend history or payout, and no Graham Number or intrinsic value estimate for fair value
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
30
25
35
20
0
AI Verdict
weak
Key drivers: Low Piotroski F-Score (2/9), Negative profitability and ROE, Zero revenue growth, High valuation relative to earnings, Lack of cash flow data
Confidence
85%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 1.82 is below sector average (avg 137.13% revenue growth, but not directly comparable)
- Price/Book of 1.37 is modest
Watchpoints
- Forward P/E of 35.50 is high without earnings growth
- No Graham Number or intrinsic value formula available
- Stock trades at a premium despite negative profitability
Future
25/100
Ref Growth rates
Positives
- 6-month price increase of +63.8% suggests strong momentum
- Analyst target price of $17.50 implies upside potential
Watchpoints
- 0% YoY revenue growth indicates stagnation
- No forward earnings growth data
- No Q/Q growth metrics available
Past
35/100
Ref Historical trends
Positives
- 52-week high of $16.70 and low of $7.87 show volatility
- 1-year return of -6.6% is better than many peers
Watchpoints
- 5-year return of -62.2% reflects long-term underperformance
- 3-year return of -47.2% indicates persistent weakness
- 1-month return of +38.5% may be unsustainable
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity (0.18)
- High current and quick ratios (4.72, 3.71)
Watchpoints
- Piotroski F-Score of 2/9 indicates weak financial health
- Negative ROE (-6.71%) and ROA (-3.52%)
- No Altman Z-Score available, but Piotroski score implies distress risk
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$14.2
Analyst Target
$17.5
Upside/Downside
+23.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ANIK and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ANIK
Anika Therapeutics, Inc.
Primary
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
|
HITI
High Tide Inc.
Peer
|
-71.8% | +84.9% | +18.3% | -32.1% | -5.7% | +0.9% |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
Peer
|
-100.0% | -99.8% | -4.1% | -27.7% | -4.4% | +10.5% |
|
OGI
Organigram Global Inc.
Peer
|
-84.9% | -32.0% | +46.1% | -22.4% | +7.0% | +9.3% |
|
PRQR
ProQR Therapeutics N.V.
Peer
|
-66.2% | -8.3% | +74.6% | -28.4% | +15.7% | +7.6% |
ANI
Anika Therapeutics, Inc.
Primary
5Y
-62.2%
3Y
-47.2%
1Y
-6.6%
6M
+63.8%
1M
+38.5%
1W
+0.6%
HIT
High Tide Inc.
Peer
5Y
-71.8%
3Y
+84.9%
1Y
+18.3%
6M
-32.1%
1M
-5.7%
1W
+0.9%
TNX
Tonix Pharmaceuticals Holding Corp.
Peer
5Y
-100.0%
3Y
-99.8%
1Y
-4.1%
6M
-27.7%
1M
-4.4%
1W
+10.5%
OGI
Organigram Global Inc.
Peer
5Y
-84.9%
3Y
-32.0%
1Y
+46.1%
6M
-22.4%
1M
+7.0%
1W
+9.3%
PRQ
ProQR Therapeutics N.V.
Peer
5Y
-66.2%
3Y
-8.3%
1Y
+74.6%
6M
-28.4%
1M
+15.7%
1W
+7.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
35.5
PEG Ratio
N/A
P/B Ratio
1.37
P/S Ratio
1.82
EV/Revenue
1.41
EV/EBITDA
-29.07
Market Cap
$204.78M
Profitability
Profit margins and return metrics
Profit Margin
-9.64%
Operating Margin
2.11%
Gross Margin
56.56%
ROE
-6.71%
ROA
-3.52%
Growth
Revenue and earnings growth rates
Revenue Growth
N/A
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.18
Low debt
Current Ratio
4.72
Strong
Quick Ratio
3.71
Excellent
Cash/Share
$4.29
Healthcare Sector Comparison
Comparing ANIK against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-6.71%
This Stock
vs
-88.14%
Sector Avg
-92.4%
(Below Avg)
Profit Margin
-9.64%
This Stock
vs
-16.28%
Sector Avg
-40.8%
(Weaker)
Debt to Equity
0.18
This Stock
vs
2.66
Sector Avg
-93.1%
(Less Debt)
Current Ratio
4.72
This Stock
vs
4.47
Sector Avg
+5.4%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | |
|
HITI
High Tide Inc.
|
BEARISH | $204.8M | - | -39.7% | -7.4% | $2.33 | Compare |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
BEARISH | $203.71M | - | -64.5% | -% | $14.34 | Compare |
|
OGI
Organigram Global Inc.
|
BEARISH | $209.6M | 13.82 | 4.6% | 6.5% | $1.52 | Compare |
|
PRQR
ProQR Therapeutics N.V.
|
BEARISH | $209.67M | - | -61.2% | -258.1% | $1.99 | Compare |
ANIK
Anika Therapeutics, Inc.
BEARISH
Mkt Cap
$205M
P/E
-
ROE
-6.7%
Price
$14.2
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | BLANCHARD CHERYL R | Director | Stock Award | 20,001 | - |
| 2026-03-09 | MCLEOD IAN W | Officer and Treasurer | Stock Award | 2,197 | - |
| 2026-03-09 | COLLERAN DAVID B J.D. | General Counsel | Stock Award | 5,465 | - |
BLANCHARD CHERYL R
Director
2026-03-09
20,001 shares
MCLEOD IAN W
Officer and Treasurer
2026-03-09
2,197 shares
COLLERAN DAVID B J.D.
General Counsel
2026-03-09
5,465 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
Barrington Research
2026-02-27
Outperform
Outperform
Barrington Research
2026-01-09
Outperform
Outperform
Barrington Research
2025-11-06
Outperform
Outperform
Barrington Research
2025-09-23
Outperform
Outperform
Past News Coverage
Recent headlines mentioning ANIK from our newsroom.
Newest → oldest
No matching news yet.